isatuximab + belumosudil + dexamethasone

**Isatuximab + belumosudil + dexamethasone** is an experimental combination regimen currently investigated for use in relapsed or refractory multiple myeloma. - **Isatuximab** is a monoclonal antibody targeting CD38, inducing tumor cell death via antibody-dependent cellular cytotoxicity, complement activation, and direct apoptosis. - **Belumosudil** is a small molecule inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2), modulating immune and fibrotic pathways. - **Dexamethasone** is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive effects, enhancing efficacy in multiple myeloma combination regimens. This specific three-drug combination is under clinical investigation (phase 1/2, umbrella trial) in relapsed/refractory multiple myeloma patients[3][4][5].